Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.57 |
| ▸ | CA2 | P00918 | 16/20 | 0.57 |
| ▸ | CA12 | O43570 | 13/20 | 0.57 |
| ▸ | CA4 | P22748 | 11/20 | 0.57 |
| ▸ | CA9 | Q16790 | 10/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634006 | 0.86 | OPRM1 (0.54) | CA1CA2CA12CA9OPRM1 | |
| Trifluoroacetic Acid SCHEMBL1881002 | 0.85 | CA1 (0.48) | CA1CA2CA12CA4CA9 | |
| SCHEMBL12634046 | 0.85 | L3MBTL1 (0.54) | CA1CA2CA12CA4CA9 | |
| SCHEMBL12633979 | 0.85 | QPCT (0.48) | CA1CA2CA12CA9OPRM1 | |
| SCHEMBL12633977 | 0.85 | LTA4H (0.58) | CA1CA2CA12CA4OPRM1 | |
| SCHEMBL12634014 | 0.85 | ALDH1A1 (0.47) | OPRM1OPRD1OPRK1 | |
| SCHEMBL12634047 | 0.81 | QPCT (0.47) | POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL12633954 | 0.79 | LTA4H (0.48) | OPRM1OPRD1OPRK1 | |
| SCHEMBL12634042 | 0.79 | HDAC1 (0.46) | POLBOPRM1OPRD1OPRK1 | |
| SCHEMBL12634004 | 0.79 | CDK1 (0.45) | POLBOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939528-B2 | Heterocycle compounds | GLAXOSMITHKLINE LLC (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054431-A1 | NOVEL HETEROCYCLE COMPOUNDS | OPRK1, OPRL1, OPRD1 | CA1 4777/4885CA2 4740/4885CA12 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.